Drugs for Acne, Rosacea and Psoriasis
January 1, 2013 (Issue: 125)
The pathogenesis of acne is multifactorial: follicular
hyperkeratinization, bacteria, sebum production,
androgens, and inflammation all play a role. The gram-positive
microaerophilic bacteria Propionibacterium
acnes promote development of acne...more
1. Adapalene-benzoyl peroxide (Epiduo) for acne. Med Lett Drugs Ther 2009; 51:31.
2. W Ting. Randomized, observer-blind, split-face study to compare the irritation potential of 2 topical acne formulations over a 14-day treatment period. Cutis 2012; 90:91.
3. Clindamycin-tretinoin (Veltin Gel) for acne. Med Lett Drugs Ther 2010; 52:102.
4. Extended-release minocycline (Solodyn) for acne. Med Lett Drugs Ther 2006; 48:95.
5. SE Garner et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2012; Aug 15 (8):CD002086.
6. Isotretinoin (Absorica) for acne. Med Lett Drugs Ther 2013; 55:8.
7. AO Arowojolu et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 7:CD004425.
8. EA Arrington et al. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis 2012; 90:83.
9. CB Turowski and WD James. The efficacy and safety of amoxicillin, trimethoprim-sulfamethoxazole, and spironolactone for treatmentresistant acne vulgaris. Adv Dermatol 2007; 23:155.
10. HC Williams et al. Acne vulgaris. Lancet 2012; 379:361.
11. J Fowler et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 2012; 166:633.
12. Low-dose doxycycline (Oracea) for rosacea. Med Lett Drugs Ther 2007; 49:5.
13. KJ Butterwick et al. Laser and light therapies for acne rosacea. J Drugs Dermatol 2006; 5:35.
14. FO Nestle et al. Psoriasis. N Engl J Med 2009; 361:496.
15. Calcipotriene for psoriasis. Med Lett Drugs Ther 1994; 36:70.
16. Calcitriol (Vectical) for mild to moderate plaque psoriasis. Med Lett Drugs Ther 2009; 51:70.
17. A betamethasone-calcipotriene combination for psoriasis. Med Lett Drugs Ther 2006; 48:55.
18. T Mudigonda et al. A review of targeted ultraviolet B phototherapy for psoriasis. J Am Acad Dermatol 2012; 66:664.
19. VM Heydendael et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349:658.
20. C Ryan et al. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol 2010; 63:949.
21. JH Saurat et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158:558.
22. J Schmitt et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159:513.
23. MH Rustin. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol 2012; 167 (suppl 3):3.
24. CL Leonardi et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014.
25. AS Paller et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358:241.
26. J Bagel et al. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol 2012; 67:86.
27. A Menter et al. Arandomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2006; 56:31.
28. A Menter et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106.
29. A Kavanaugh et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60:976.
30. Ustekinumab (Stelara) for psoriasis. Med Lett Drugs Ther 2010; 52:7.
31. KA Papp et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675.
32. K Reich et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011; 365:1586.
33. BE Strober et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011;165:661.
34. C Ryan et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306:864.
35. T Tzellos et al. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2012; March 8 (epub).
36. K Papp et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380:738.
37. KA Papp et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dosecomparison study. J Eur Acad Dermatol Venereol. 2012 Oct 3 (epub).
38. Tofacitinib (Xeljanz) for rheumatoid arthritis. Med Lett Drugs Ther 2013; 55:1.
39. KA Papp et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167:668.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
